---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Diagnosis"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Diagnosis. Topics: Diagnostic criteria: ICSD-3-TR as reproduced in the VA/DoD guideline; Diagnostic criteria: ICSD-3 definition as stated in the AASM diagnostic testing guideline; Diagnostic testing: AASM 2017 guideline recommendations on polysomnography and home sleep apnea testing; Home sleep apnea testing: candidate criteria, device requirements, and respiratory event index; 13 further topics. 17 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/diagnosis"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Diagnostic criteria: ICSD-3-TR as reproduced in the VA/DoD guideline

> “Diagnostic Criteria ((A and B) or C) + D must be met A. The presence of one or more of the following: 1. The patient complains of sleepiness, fatigue, insomnia, or other symptoms leading to impaired sleep-related quality of life. 2. The patient wakes with breath holding, gasping, or choking 3. The bed partner or other observer reports habitual snoring or breathing interruptions during the patient's sleep B. PSG or HSAT demonstrates: 1. Five or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT) C. PSG or HSAT demonstrates: 1. Fifteen or more predominantly obstructive respiratory events (obstructive and mixed apneas, hypopneas, or respiratory effort related arousals [RERAs]) per hour of sleep during a PSG or per hour of monitoring (HSAT) D. The symptoms are not better explained by another current sleep disorder, medical disorder, medication or substance use.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-2"></a>

### Diagnostic criteria: ICSD-3 definition as stated in the AASM diagnostic testing guideline

> “The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index (RDI) ≥ 5 events/h associated with the typical symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas), or an obstructive RDI ≥ 15 events/h (even in the absence of symptoms).”
> “In addition to apneas and hypopneas that are included in the AHI, the RDI includes respiratory effort-related arousals (RERAs).”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.5-3"></a>

### Diagnostic testing: AASM 2017 guideline recommendations on polysomnography and home sleep apnea testing

> “Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up. Polysomnography is the standard diagnostic test for the diagnosis of OSA in adult patients in whom there is a concern for OSA based on a comprehensive sleep evaluation.”
> “We recommend that clinical tools, questionnaires and prediction algorithms not be used to diagnose OSA in adults, in the absence of polysomnography or home sleep apnea testing. (STRONG)”
> “We recommend that polysomnography, or home sleep apnea testing with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA. (STRONG)”
> “We recommend that if a single home sleep apnea test is negative, inconclusive, or technically inadequate, polysomnography be performed for the diagnosis of OSA. (STRONG)”
> “We recommend that polysomnography, rather than home sleep apnea testing, be used for the diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia. (STRONG)”
> “We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a full-night diagnostic protocol for polysomnography be used for the diagnosis of OSA. (WEAK)”
> “We suggest that when the initial polysomnogram is negative and clinical suspicion for OSA remains, a second polysomnogram be considered for the diagnosis of OSA. (WEAK)”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.5-4"></a>

### Home sleep apnea testing: candidate criteria, device requirements, and respiratory event index

> “An increased risk of moderate to severe OSA is indicated by the presence of excessive daytime sleepiness and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension.”
> “A technically adequate HSAT device incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or else PAT with oximetry and actigraphy.”
> “A technically adequate diagnostic test includes a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period.”
> “Measurement error is inevitable in HSAT, compared against PSG, as standard sleep staging channels are not typically monitored in HSAT (e.g., EEG, EOG and EMG monitoring are not typically performed), which results in use of the recording time rather than sleep time to define the denominator of the respiratory event index (REI; the term used to represent the frequency of apneas and hypopneas derived from HSAT).”
> “HSAT devices that use conventional sensors are unable to detect hypopneas only associated with cortical arousals, which are included in the recommended AHI scoring rule in the AASM Scoring Manual.”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.5-5"></a>

### Screening and diagnostic testing: VA/DoD 2025 Recommendations 1 to 4

> “1. For screening of patients with sleep complaints, we suggest using validated screening instruments for both insomnia (e.g., Insomnia Severity Index or Athens Insomnia Scale) and obstructive sleep apnea (e.g., STOP) to identify patients who need further evaluation. Weak for Not reviewed, Amended”
> “2. For diagnosis of clinically suspected obstructive sleep apnea, we recommend diagnosis with polysomnography or home sleep apnea testing. Strong for Reviewed, New-added”
> “3. For diagnosis of obstructive sleep apnea in appropriate patients*, we suggest home sleep apnea testing as an alternative to in-laboratory polysomnography. Weak for Reviewed, New- replaced”
> “4. For diagnosis of patients with a non-diagnostic home sleep apnea test, we recommend further sleep testing for obstructive sleep apnea with in-lab polysomnography or HSAT. Strong for Reviewed, New- replaced”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-6"></a>

### Screening: STOP questionnaire scoring in the VA/DoD guideline

> “High risk of OSA: answering yes to two or more questions Low risk of OSA: answering yes to less than two questions”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-7"></a>

### Severity thresholds: VA/DoD 2025 guideline, AHI on HSAT and severity for treatment selection

> “Sidebar 8. AHI 5 to <15 on HSAT 1. Treatment for OSA is recommended for symptomatic patients with an AHI or REI of 5 to <15 events per hour 2. For patients who will have limitations to their work and/or lifestyle, definitive testing with an in-lab PSG is recommended 3. For the general population without such restrictions, an AHI of 5 to <15 events per hour on HSAT should be treated as OSA”
> “1. Prescribe PAP as first line therapy for patient with severe OSA (i.e., AHI >30 events per hour) 2. Prescribe PAP or MAD for other OSA severity (i.e., AHI 5 to <30 events per hour), based on clinical evaluation, comorbidities, and patient preference.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.1.5-8"></a>

### Severity thresholds: AASM 2009 adult OSA clinical guideline

> “The diagnosis of OSA is confirmed if the number of obstructive events (apneas, hypopneas + respiratory event related arousals) on PSG is greater than 15 events/hr or greater than 5/hour in a patient who reports any of the following: unintentional sleep episodes during wakefulness; daytime sleepiness; unrefreshing sleep; fatigue; insomnia; waking up breath holding, gasping, or choking; or the bed partner describing loud snoring, breathing interruptions, or both during the patient's sleep.”
> “OSA severity is defined as mild for RDI ≥ 5 and < 15, moderate for RDI ≥ 15 and ≤ 30, and severe for RDI > 30/hr (Consensus).”

Source: [Epstein et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2699173/)

<a id="topic-2.2.1.5-9"></a>

### Severity thresholds: 1999 AASM task force grades and their consensus basis

> “They also recommended severity criteria based on degree of sleepiness and frequency of respiratory events, with the following severity grades based on the number of obstructive breathing events per hour:”
> “Mild: 5 to 15 events per hour”
> “Moderate: >15 to 30 events per hour”
> “Severe: greater than 30 events per hour”
> “It should be noted that these recommendations were based on expert consensus, with an acknowledgment that the data on which to base these event definitions and severity measures were limited.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

<a id="topic-2.2.1.5-10"></a>

### Scoring rules: AASM 2012 recommended hypopnea rule with 3% desaturation or arousal, and 4% rule for reimbursement

> “Score a respiratory event as a hypopnea if all of the following are met:”
> “The peak signal excursions drop by ≥ 30% of pre-event baseline using nasal pressure (diagnostic study), PAP device flow (titration study), or an alternative hypopnea sensor.”
> “The duration of the ≥ 30% drop in signal excursions is ≥ 10 seconds.”
> “There is ≥ 3% oxygen desaturation from pre-event baseline or the event is associated with an arousal.”
> “Note: If necessary, the number of hypopneas using a definition requiring ≥ 30% drop in flow for ≥ 10 seconds that is associated with ≥ 4% desaturation may additionally be reported to qualify a patient for PAP reimbursement (e.g., Medicaid or Medicare patients).”
> “For Medicaid and Medicare patients the use of a hypopnea definition based on a 30% drop in flow and 4% or greater desaturation will need to be used to ensure reimbursement until reimbursement policies are changed to reflect the new hypopnea definition.”

Source: [Berry et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3459210/)

<a id="topic-2.2.1.5-11"></a>

### Scoring rules: AASM 2012 adult apnea rule

> “Score a respiratory event in adults as an apnea if both of the following are met:”
> “There is a drop in the peak signal excursion by ≥ 90% of pre-event baseline using an oronasal thermal sensor (diagnostic study), positive airway pressure device flow (titration study), or an alternative apnea sensor.”
> “The duration of the ≥ 90% drop in sensor signal is ≥ 10 seconds.”

Source: [Berry et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3459210/)

<a id="topic-2.2.1.5-12"></a>

### Effect of the hypopnea definition on the AHI: 3% versus 4% desaturation

> “Recognizing the apparent equivalence of hypopnea definitions requiring ≥ 3% or ≥ 4% desaturation, the task force has recommended adoption of the 3% criterion.”
> “with median AHI in a general community sample being almost twice as great using a 3% as a 4% criterion”
> “Therefore, thresholds for identification of the presence and severity of OSA, and for inferring health-related consequences of OSA, must be calibrated to the hypopnea definition employed.”

Source: [Berry et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3459210/)

<a id="topic-2.2.1.5-13"></a>

### Effect of the hypopnea definition on the AHI: three AASM definitions in clinical polysomnography

> “For AHIRec, hypopneas were required to have ≥ 30% airflow reduction and ≥ 4% desaturation; and for AHIAlt, hypopneas were required to have ≥ 50% airflow reduction and ≥ 3% desaturation or arousal. The median AHIRec was approximately 30% of the median AHIChicago, whereas the median AHIAlt was approximately 60% of the AHIChicago, with large, AHI-dependent, patient-specific differences observed.”
> “Failure to adjust cut-points for the new criteria would result in approximately 40% of patients previously classified as positive for OSA using AHIChicago being negative using AHIRec and 25% being negative using AHIAlt.”
> “This study demonstrates that using different published standard hypopnea definitions leads to marked differences in AHI.”

Source: [Ruehland et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2635578/)

<a id="topic-2.2.1.5-14"></a>

### Medicare coverage thresholds: CPAP national coverage determination, AHI or RDI with 4% desaturation hypopnea rule

> “Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% oxygen desaturation.”
> “The AHI and/or RDI may be measured by polysomnography (PSG) in a facility-based sleep study laboratory, or by a Type II home sleep test (HST) monitor, a Type III HST monitor, or a Type IV HST monitor measuring at least 3 channels.”
> “An initial 12-week period of CPAP is covered in adult patients with OSA if either of the following criterion using the AHI or RDI are met:”
> “AHI or RDI greater than or equal to 15 events per hour, or”
> “AHI or RDI greater than or equal to 5 events and less than or equal to 14 events per hour with documented symptoms of excessive daytime sleepiness, impaired cognition, mood disorders or insomnia, or documented hypertension, ischemic heart disease, or history of stroke.”
> “If the AHI or RDI is calculated based on less than 2 hours of continuous recorded sleep, the total number of recorded events to calculate the AHI or RDI during sleep testing must be at a minimum the number of events that would have been required in a 2-hour period.”

Source: [CMS National Coverage Determination 240.4 (2008)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=226)

<a id="topic-2.2.1.5-15"></a>

### Medicare coverage of sleep tests: national coverage determination for sleep testing

> “1. Type I PSG is covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed attended in a sleep lab facility.”
> “2. Type II or Type III sleep testing devices are covered when used to aid the diagnosis of OSA in beneficiaries who have clinical signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.”
> “3. Type IV sleep testing devices measuring three or more channels, one of which is airflow, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.”
> “4. Sleep testing devices measuring three or more channels that include actigraphy, oximetry, and peripheral arterial tone, are covered when used to aid the diagnosis of OSA in beneficiaries who have signs and symptoms indicative of OSA if performed unattended in or out of a sleep lab facility or attended in a sleep lab facility.”

Source: [CMS National Coverage Determination 240.4.1 (2009)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=330)

<a id="topic-2.2.1.5-16"></a>

### Sleepiness assessment: Epworth Sleepiness Scale

> “This is a simple, self-administered questionnaire which is shown to provide a measurement of the subject's general level of daytime sleepiness.”
> “They rated the chances that they would doze off or fall asleep when in eight different situations commonly encountered in daily life.”
> “In patients with obstructive sleep apnea syndrome ESS scores were significantly correlated with the respiratory disturbance index and the minimum SaO2 recorded overnight.”

Source: [Johns (1991)](https://pubmed.ncbi.nlm.nih.gov/1798888/)

<a id="topic-2.2.1.5-17"></a>

### Metrics beyond the AHI: hypoxic burden and limits of the AHI

> “Apnoea–hypopnoea index (AHI), the universal clinical metric of sleep apnoea severity, poorly predicts the adverse outcomes of sleep apnoea, potentially because the AHI, a frequency measure, does not adequately capture disease burden.”
> “The hypoxic burden was determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline.”

Source: [Azarbarzin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6451769/)

> “Although the AHI is often criticized for its limitations, it remains the best studied metric of OSA severity, albeit imperfect. We further review the potential value of alternative metrics including hypoxic burden, arousal intensity, odds ratio product, and cardiopulmonary coupling.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
